No Picture
Trading Ideas

UPDATE 1-GameStop cuts full-year profit forecast, shares slump 21%

GameStop Corp reported a plunge in quarterly sales and slashed its full-year profit forecast on Tuesday, as the company struggles with consumers delaying purchases ahead of the launch of new consoles, sending its shares plunging 21%. Latest versions of Sony Corp’s PlayStation and Microsoft Corp’s Xbox are due to be unveiled next year, with video game and console retailers also hit by the shift to downloadable or streamable games and away from physical versions. GameStop now sees full-year earnings per share in the range of 10 cents to 20 cents, down from an earlier forecast of $1.15 to …read more […]

No Picture
Trading Ideas

UPDATE 1-Chevron expects $10 bln-$11 bln charge in fourth quarter; plans sale of assets

U.S. oil major Chevron Corp said on Tuesday it is evaluating strategic alternatives, including divestment of gas-related assets in Appalachia shale, Kitimat LNG, and other international projects. Chevron, which set a 2020 spending program of $20 billion, said these actions are estimated to result in non-cash, after tax impairment charges of $10 billion to $11 billion in its fourth quarter, with more than half related to the Appalachia shale. Chevron reported a 36% drop in third-quarter profit, hit by lower oil and gas prices and refining margins, and warned higher costs would affect its current-quarter results. …read more […]

No Picture
Business News

Wall Street slips as tariff deadline closes in

Wall Street’s main stock indexes ended slightly lower on Tuesday, though not far from record highs, as investors awaited concrete news on whether a new round of U.S. tariffs on Chinese goods would take effect on Dec. 15, a potential turning point in a trade dispute between the world’s two largest economies that has convulsed markets.

…read more […]

No Picture
Trading Ideas

It’s Time to Ride Your Winners

Alan “Ace” Greenberg was a legend on Wall Street. Greenberg arrived at Bear Stearns in 1949 with no experience in financial markets.
Starting from the bottom rung of the trading floor, Greenberg rose through the ranks to become CEO in 1978, a position he held until 1993.
Greenberg was executive chairman when Bear was forced to sell itself to J.P. Morgan during the financial crisis, a sad ending to an otherwise glorious career.
Although he had no formal background in securities or trading, Greenberg thrived on the trading floor. A former college football player, he was physically and mentally tough. He was known …read more […]

No Picture
Trading Ideas

Cisco Systems Is Now Trading in the Bargain Bin

When you’re looking for so-called “value” in year No. 10 of a bull market, it’s not easy to find quality companies trading in Wall Street’s bargain bin.
However, there’s one company I’d like to bring to your attention today which I feel could offer you the best “buy low” opportunity within the entire technology sector.
In today’s Trade of the Day, I’ll tell you the name of the company, why I like it and exactly how members are playing it right now in The War Room.
So let’s get started…
The company that’s now a tech bargain is Cisco Systems (Nasdaq: CSCO).
As I’m sure …read more […]

No Picture
Trading Ideas

Hedge Funds Are Really Crazy About KEMET Corporation (KEM)

Hedge funds are known to underperform the bull markets but that’s not because they are terrible at stock picking. Hedge funds underperform because their net exposure in only 40-70% and they charge exorbitant fees. No one knows what the future holds and how market participants will react to the bountiful news that floods in each […] …read more […]

No Picture
Trading Ideas

UPDATE 1-Correvio suffers fresh blow as heart drug fails to win FDA panel backing

Independent experts to the U.S. Food and Drug Administration on Tuesday voted against Correvio Pharma Corp’s drug to correct irregular rhythm in the upper chambers of the heart in adult patients, the latest setback to the company’s efforts to market a potential blockbuster in the country. The panel voted 11-2 against approving the drug, Brinavess, citing serious safety risks, including low blood pressure and irregular rhythm in the lower heart chambers, and deaths during the trials. “It clearly has benefit but it does have risk,” said panel member Dr. Barry Davis of the University of Texas School …read more […]